Patent: 9,206,251
✉ Email this page to a colleague
Summary for Patent: 9,206,251
Title: | Nucleic acids encoding anti-C5 antibodies having improved pharmacokinetics |
Abstract: | The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human. |
Inventor(s): | Andrien, Jr.; Bruce A. (Guilford, CT), Sheridan; Douglas L. (Branford, CT), Tamburini; Paul P. (Kensington, CT) |
Assignee: | Alexion Pharmaceuticals, Inc. (Cheshire, CT) |
Application Number: | 14/789,329 |
Patent Claims: | see list of patent claims |
Details for Patent 9,206,251
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Alexion Pharmaceuticals, Inc. | ULTOMIRIS | ravulizumab-cwvz | Injection | 761108 | 12/21/2018 | ⤷ Try a Trial | 2034-03-07 |
Alexion Pharmaceuticals, Inc. | ULTOMIRIS | ravulizumab-cwvz | Injection | 761108 | 10/09/2020 | ⤷ Try a Trial | 2034-03-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,206,251
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 099698 | ⤷ Try a Trial |
Australia | 2015226977 | ⤷ Try a Trial |
Australia | 2019236617 | ⤷ Try a Trial |
Australia | 2020267324 | ⤷ Try a Trial |
Brazil | 112016020454 | ⤷ Try a Trial |
Canada | 2942165 | ⤷ Try a Trial |
Canada | 3166772 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |